mAbs (biosimilars) as tools to research novel new therapies and uncover effective off-target application.
Research Grade Biosimilar Antibodies from ProSci
Therapeutic antibodies dominate pipelines and top selling drugs at major pharmaceutical companies. They have proven to be valuable tools in the fight against diseases from cancer and autoimmune disorders to infectious and neurodegenerative diseases. Beyond therapeutics, monoclonal antibodies shown to
The Role of Monoclonal Antibodies & Biosimilars in Research – ProSci Inc.
With more than 800 Research Grade Biosimilar antibodies in ProSci’s catalogue, these unique tools are available for researchers worldwide. Explore the world of biosimilars! In 1986, the first monoclonal antibody became licensed–an event occurring nine years after the generation of